Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention

Circulation

Volumn 108, Issue 17, 2003, Pages 2154-2169

  Sarnak, Mark J ^a   Levey, Andrew S ^a   Schoolwerth, Anton C ^a   Coresh, Josef ^a   Culleton, Bruce ^a   Hamm, L Lee ^a   McCullough, Peter A ^a   Kasiske, Bertram L ^a   Kelepouris, Ellie ^a   Klag, Michael J ^a   Parfrey, Patrick ^a   Pfeffer, Marc ^a   Raij, Leopoldo ^a   Spinosa, David J ^a   Wilson, Peter W ^a  

^a NONE

Author keywords

AHA Scientific Statements; Cardiovascular diseases; Kidney; Risk factors

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; DIABETIC NEPHROPATHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DIABETIC NEPHROPATHIES; DIALYSIS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PREVALENCE; PROTEINURIA; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0141468244     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000095676.90936.80     Document Type: Review

References (189)

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 1998 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998. Available at: http://www.usrds.org/adr_1998.htm. Accessed September 12, 2003.
2. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 2000 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000, Available at: http://www.usrds.org/atlas_2000.htm. Accessed September 12, 2003.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
4. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13(5 suppl):I80-I93.
5. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32:853-906.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32: S112-S119.
7. American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, Tex: American Heart Association; 2002. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000090. Accessed September 12, 2003.
8. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
9. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-354.
10. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84:985-992.
11. Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation. 1995;60:908-914.
12. Hernandez D, Lacalzada J, Rufino M, et al. Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting enzyme gene. Kidney Int. 1997;51:1205-1211.
13. Peteiro J, Alvarez N, Calvino R, et al. Changes in left ventricular mass and filling after renal transplantation are related to changes in blood pressure: an echocardiographic and pulsed Doppler study. Cardiology. 1994;85:273-283.
14. Huting J. Course of left ventricular hypertrophy and function in end-stage renal disease after renal transplantation. Am J Cardiol. 1992;70:1481-1484.
15. Himelman RB, Landzberg JS, Simonson JS, et al. Cardiac consequences of renal transplantation: changes in left ventricular morphology and function. J Am Coll Cardiol. 1988;12:915-923.
16. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 1997 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1997. Available at: http://www.usrds.org/adr_1997.htm. Accessed September 15, 2003.
17. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353-362.
18. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186-192.
19. Warram JH, Gearin G, Laffel L, et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7:930-937.
20. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care. 2001;24(suppl 1):S1-S133. [See pp S69-S72.]
21. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004-1010.
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
23. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
25. Obrador GT, Arora P, Kausz AT, et al. Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney Int. 1999;56:2227-2235.
26. Levey AS. Clinical practice: non-diabetic kidney disease. N Engl J Med. 2002;347:1505-1511.
27. Remuzzi G, Schieppatti A, Ruggenenti P. Clinical practice: nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145-1151.
28. London GM, Marchais SJ, Guerin AP, et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant. 2002;17:1713-1724.
29. Tonelli M, Bohm C, Pandeya S, et al. Cardiac risk factors and use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484-489.
30. Jungers P, Massy ZA, Khoa TN, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997;12:2597-2602.
31. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15:218-223.
32. Rabbat CG, Treleaven DJ, Russell JD, et al. Prognostic value of myocardial perfusion studies in patients with end stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol. 2003;14:431-439.
33. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int. 1984;25:653-659.
34. Mitchell GF, Izzo JL, Lacourciere Y, et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation. 2002;105:2955-2961.
35. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434-2439.
36. Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension. 1998;32:570-574.
37. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-992.
38. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548-1555.
39. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int. 1995;47:884-890.
40. Harnett JD, Murphy B, Collingwood P, et al. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients. Nephron. 1993;65:212-214.
41. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 suppl 1):S117-S131.
42. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:356-362.
43. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
44. Foley RN, Parfrey PS, Harnett JD, et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995;5:2024-2031.
45. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33:507-517.
46. Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561-569. Erratum in: Kidney Int. 1998;54:1417.
47. Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int. 1998;54:561-569. Erratum in: Kidney Int. 1998;54:1417.
48. Iseki K, Yamazato M, Tozawa M, et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-1893.
49. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458-482.
50. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996;49:1379-1385.
51. Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002;13:1918-1927.
52. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002;57:327-335.
53. Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial. 2003;16:118-127.
54. National Kidney Foundation K/DOQI clinical practice guidelines on managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 3):S1-S77.
55. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999;56:1078-1083.
56. Bostom AG, Shemin D, Verhouf P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: a prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554-2558.
57. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002;61:609-614.
58. Zimmerman J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
59. Wahn F, Daniel V, Kronenberg F, et al. Impact of apolipoprotein(a) phenotypes on long-term renal transplant survival. J Am Soc Nephrol. 2001;12:1052-1058.
60. Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the CHOICE study. Circulation. 2002;106:2812-2818.
61. Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027-1036.
62. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
63. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int. 2001;59:407-414.
64. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
65. Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014-1021.
66. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
67. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int. 2002;61:S44-S48.
68. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469-476.
69. Ma JZ, Ebben J, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610-619.
70. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
71. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet. 2000;356:1213-1218.
72. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992-995.
73. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154-160.
74. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799-805.
75. Donahue RP, Goldberg RJ, Chen Z, et al. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol. 1993;46:245-252.
76. Dimeny EM. Cardiovascular disease after renal transplantation. Kidney Int. 2002;61:S78-S84.
77. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307-313.
78. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995;60:451-457.
79. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11:1735-1743.
80. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347:797-805.
81. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
82. Lee KU, Park JY, Kim SW, et al. Prevalence and associated features of albuminuria in Koreans with NIDDM. Diabetes Care. 1995;18:793-799.
83. Mykkanen L, Zaccaro DJ, O'Leary DH, et al. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects: the insulin resistance atherosclerosis study (IRAS). Stroke. 1997;28:1710-1716.
84. Suzuki K, Kato K, Hanyu O, et al. Left ventricular mass index increases in proportion to the progression of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract. 2001;54:173-180.
85. Stephenson JM, Kenny S, Stevens LK, et al. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med. 1995;12:149-155.
86. Schleiffer T, Holken H, Brass H. Morbidity in 565 type 2 diabetic patients according to stage of nephropathy. J Diabetes Complications. 1998;12:103-109.
87. Howard BV, Lee ET, Cowan LD, et al. Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart study. Am J Epidemiol. 1995;142:254-268.
88. John L, Rao PS, Kanagasabapathy AS. Prevalence of diabetic nephropathy in non-insulin dependent diabetics. Indian J Med Res. 1991;94:24-29.
89. Agewall S, Wikstrand J, Ljungman S, et al. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol. 1997;80:164-169.
90. Gall MA, Borch-Johnsen K, Hougaard P, et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309.
91. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418.
92. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
93. Messent JW, Elliott TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int. 1992;41:836-839.
94. Miettinen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033-2039.
95. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996;313:779-784.
96. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157-1165.
97. Uusitupa MI, Niskanen LK, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-1184.
98. Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093-1100.
99. Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin dependent diabetes mellitus. Lancet. 1992;340:319-323.
100. Stehouwer CD, Lambet J, Donker AJ, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55-68.
101. Festa A, D'Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int. 2000;58:1703-1710.
102. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med. 1998;338:1202-1211.
103. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 suppl 3):S142-S156.
104. Pontremoli R, Sofia A, Ravera M, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC study. Microalbuminuria: a Genoa Investigation on Complications. Hypertension. 1997;30:1135-1143.
105. Dell'Omo G, Penno G, Giorgi D, et al. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002;40:1-8.
106. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519-526.
107. Bigazzi R, Bianchi S, Nenci R, et al. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens. 1995;9:827-833.
108. Wachtell K, Palmieri V, Olsen MH, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J. 2002;143:319-326.
109. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens. 2002;20:405-412.
110. Diercks GF, Hillege HL, van Boven A, et al. Relation between albumin in the urine and electrocardiographic markers of myocardial ischemia in patients without diabetes mellitus. Am J Cardiol. 2001;88:771-774.
111. Culleton BF, Larson MG, Parfrey PS, et al. Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study. Am J Med. 2000;109:1-8.
112. De Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol. 2002;13:2213-2222.
113. Diercks GF, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol. 2002;40:1401-1407.
114. Damsgaard EM, Froland A, Jorgensen OD, et al. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300:297-300.
115. Grimm RJ, Svendsen K, Kasiske B, et al. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group: Multiple Risk Factor Intervention Trial. Kidney Int. 1997;63:S10-S14.
116. Ljungman S, Wikstrand J, Hartford M, et al. Urinary albumin excretion - a predictor of risk of cardiovascular disease: a prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens. 1996;9:770-778.
117. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
118. Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:617-624.
119. Kannel WB, Stampfer MJ, Castelli WP, et al. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984;108:1347-1352.
120. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745-753.
121. Kuusisto J, Mykkanen L, Pyorala K, et al. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation. 1995;91:831-837.
122. Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation. 2001;103:3057-3061.
123. Ordonez JD, Hiatt RA, Killebrew EJ, et al. The increased risk of coronary artery disease associated with nephrotic syndrome. Kidney Int. 1993;44:638-642.
124. Wagner DK, Harris T, Madans JH. Proteinuria as a biomarker: risk of subsequent morbidity and mortality. Environ Res. 1994;66:160-172.
125. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington diabetes survey. Lancet. 1988;2(8610):530-533.
126. Pedrinelli R, Dell'Omo G, Penno G, et al. Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med. 2001;6:257-264.
127. Gosling P. Microalbuminuria: a marker of systemic disease. Br J Hosp Med. 1995;54:285-290.
128. Clausen P, Feldt-Rasmussen B, Jensen G, et al. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci. 1999;97:37-43.
129. Jensen JS. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1324-1329.
130. Clausen P, Jensen JS, Jensen G, et al. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103:1869-1874.
131. Paisley KE, Beaman M, Tooke JE, et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 2003;63:624-633.
132. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-2219.
133. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
134. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular disease in the community. J Am Coll Cardiol. 2003;41:47-55.
135. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol. 2001;12:218-225.
136. Shlipak MG, Fried LF, Crump C, et al. Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int. 2002;62:997-1004.
137. Reis SE, Olson MB, Fried L, et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation. 2002;105:2826-2829.
138. Manjunath G, Tighiouart H, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121-1129.
139. Friedman PJ. Serum creatinine: an independent predictor of survival after stroke. J Intern Med. 1991;229:175-179.
140. McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol. 2000;36:679-684.
141. McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med. 2002;162:2464-2468.
142. Soman SS, Sandberg KR, Borzak S, et al. The independent association of renal dysfunction and arrhythmias in critically ill patients. Chest. 2002;122:669-677.
143. Matts JP, Karnegis JN, Campos CT, et al. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. J Fam Pract. 1993;36:497-503.
144. Walsh CR, O'Donnell CJ, Camargo CA, et al. Elevated serum creatinine is associated with 1-year mortality after myocardial infarction. Am Heart J. 2002;144:1003-1011.
145. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era. Circulation. 2000;102:2966-2972.
146. Hemmelgarn BR, Ghali WA, Quan H, et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis. 2001;37:64-72.
147. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001;37:1191-1200. Erratum in: Am J Kidney Dis. 2001;38:701.
148. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001;37:1191-1200. Erratum in: Am J Kidney Dis. 2001;38:701.
149. Shlipak MG, Simon JA, Grady D, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;38:705-711.
150. Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infaretion in elderly patients. Ann Intern Med. 2002;137:555-562.
151. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
152. Kearney MT, Fox KA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801-1808.
153. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203-210.
154. McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13:1928-1936.
155. Mahon NG, Blackstone EH, Francis GS, et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 2002;40:1106-1113.
156. Szczech LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int. 2001;60:292-299.
157. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. Circulation. 2002;105:2253-2258.
158. Gruberg L, Weissman NJ, Waksman R, et al. Comparison of outcomes after percutaneous coronary revascularization with stents in patients with and without mild chronic renal insufficiency. Am J Cardiol. 2002;89:54-57.
159. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980.
160. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113-1119.
161. Beddhu S, Allen-Brady K, Cheung AK, et al. Impact of renal failure on the risk of myocardial infarction and death. Kidney Int. 2002;62:1776-1783.
162. Januzzi JL, Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) trial. Circulation. 2002;105:2361-2366.
163. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002;137:563-570.
164. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585-592.
165. Manolio TA, Kronmal RA, Burke GL, et al. Short-term predictors of incident stroke in older adults: the Cardiovascular Health Study. Stroke. 1996;27:1479-1486.
166. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
167. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn study. Kidney Int. 2002;62:1402-1407.
168. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161:886-891.
169. Flack JM, Neaton JD, Daniels B, et al. Ethnicity and renal disease: lessons from the multiple risk factor intervention trial and the treatment of mild hypertension study. Am J Kidney Dis. 1993;21(4 supp 1):31-40.
170. Shaw RE, Anderson HV, Brindis RG, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol. 2002;39:1104-1112.
171. O'Brien MM, Gonzales R, Shroyer AL, et al. Modest serum creatinine elevation affects adverse outcome after general surgery. Kidney Int. 2002;62:585-592.
172. Garg AX, Clark WF, Haynes RB, et al. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61:1486-1494.
173. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28:557-563.
174. Gruberg L, Weissman NJ, Pichard AD, et al. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J. 2003;145:529-534.
175. Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41:718-724.
176. Wison S, Foo K, Cunningham J, et al. Renal function and risk stratification in acute coronary syndromes. Am J Cardiol. 2003;91:1051-1054.
177. Anderson RJ, O'Brien M, MaWhinney S, et al. Mild renal failure is associated with adverse outcome after cardiac valve surgery. Am J Kidney Dis. 2000;35:1127-1134.
178. Anderson RJ, O'Brien M, MaWhinney S, et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery: VA Cooperative Study #5. Kidney Int. 1999;55:1057-1062.
179. Reinecke H, Trey T, Matzkies F, et al. Grade of chronic renal failure, and acute and long term outcome after percutaneous coronary interventions. Kidney Int. 2003;63:696-701.
180. Rubenstein MH, Sheynberg BV, Harrell LC, et al. Effectiveness of and adverse events after percutaneous coronary intervention in patients with mild versus severe renal failure. Am J Cardiol. 2001;87:856-860.
181. Reddan DN, Szczech LA. Renal insufficiency and the risk of cardiovascular mortality. Kidney Int. 2002;62:1474-1475.
182. Arnadottir M, Hultberg B, Nilsson-Ehle P, et al. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest. 1996;56:41-46.
183. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87-92.
184. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144:226-232.
185. Reddan DN, O'Shea JC, Sarembock IJ, et al. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). Am J Cardiol. 2003;91:17-21.
186. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
187. Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13:1084-1090.
188. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
189. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.